CLDX

Celldex Therapeutics, Inc.

Price Chart

Latest Quote

$32.43

-0.50 (-1.52%)

Current Price

Previous Close	$32.93
Open	$33.69
Day High	$34.09
Day Low	$32.36
Volume	1,832,270

Fetched: 2026-06-20T02:41:30

Stock Information

Shares Outstanding	78.49M
Total Debt	$1.91M
Cash Equivalents	$451.46M
Revenue	$865K
Net Income	$-283.65M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$2.55B
EPS (TTM)	$-4.27
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$2.09B
Sales	$865K
Income	$-283.65M
Book/sh	$6.85
Cash/sh	$5.75
Employees	198

Financial Ratios

Quick Ratio	8.78
Current Ratio	8.92
Debt/Eq	0.42

Returns & Margins

ROA	-30.89%
ROE	-48.94%
Operating Margin	-562900.00%

Ownership

Insider Ownership	0.27%
Institutional Ownership	94.91%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-7.21
P/S	2942.77
P/B	4.73

Analyst Data

Recommendation	strong_buy
Target Price	$57.53

Technical Indicators

SMA20	$30.64
SMA50	$32.02
SMA200	$28.00
RSI	54.85
ATR	1.2300

Shares Float	72.46M
Short Float	10.80%
Short Ratio	10.27
Volatility	0.93
Rel Volume	2.75

Performance History

Week	+8.24%
Month	+7.56%
Quarter	+7.99%
6 Months	+21.55%
YTD	+20.07%
Year	+61.67%
3 Years	-15.28%
5 Years	+4.48%
10 Years	-50.98%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$32.43	2,378,400
2026-06-17	$32.93	991,600
2026-06-16	$32.32	999,400
2026-06-15	$32.12	1,007,200
2026-06-12	$31.27	599,800
2026-06-11	$29.96	982,700
2026-06-10	$29.35	490,400
2026-06-09	$29.60	616,900
2026-06-08	$28.56	629,700
2026-06-05	$28.62	1,273,500
2026-06-04	$29.93	592,000
2026-06-03	$29.77	876,100
2026-06-02	$28.90	918,500
2026-06-01	$30.14	1,020,300
2026-05-29	$31.43	494,700
2026-05-28	$31.70	727,100
2026-05-27	$31.65	503,000
2026-05-26	$30.85	726,200
2026-05-22	$30.73	582,900
2026-05-21	$30.58	904,400
2026-05-20	$30.90	738,800
2026-05-19	$30.15	566,600

About Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

📰 Latest News

Celldex Therapeutics (CLDX) Stock Valuation Check After Recent Share Price Momentum

Simply Wall St. • 2026-06-15T00:16:24Z

Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Pullback And Mixed Signals

Simply Wall St. • 2026-05-12T22:17:19Z

Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates

Zacks • 2026-05-07T21:55:03Z

Innoviva (INVA) Tops Q1 Earnings Estimates

Zacks • 2026-05-07T01:45:06Z

Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High?

Zacks • 2026-05-04T13:55:05Z

Is Celldex Therapeutics (CLDX) Still Attractive After A 70% One Year Share Price Jump

Simply Wall St. • 2026-04-25T21:07:33Z

Celldex Therapeutics Spotlights Barzolvolimab as Phase III CSU Data Looms After Fast Enrollment

MarketBeat • 2026-04-15T07:33:03Z

Celldex shares plunge after dumping $300 million stock deal

GuruFocus.com • 2026-04-02T16:26:26Z

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday as Escalation Signals in Iran Conflict Lift Oil Prices

MT Newswires • 2026-04-02T13:10:17Z

Is Celldex’s US$300 Million Follow-On To Fund Barzolvolimab Altering The Investment Case For CLDX?

Simply Wall St. • 2026-04-02T11:18:47Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$1,545,000	$7,020,000	$6,883,000	$2,357,000
Operating Revenue	$1,545,000	$7,020,000	$6,883,000	$2,357,000
Expenses
Total Expenses	$288,912,000	$202,098,000	$148,925,000	$109,453,000
Other Income Expense	$28,610,000	$37,215,000	$613,000	$-5,229,000
Operating Expense	$288,912,000	$202,098,000	$148,925,000	$109,453,000
General And Administrative Expense	$43,838,000	$38,548,000	$30,914,000	$27,195,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-258,757,000	$-157,863,000	$-141,429,000	$-112,325,000
Normalized Income	$-287,367,000	$-195,078,000	$-142,042,000	$-107,096,000
Net Income From Continuing And Discontinued Operation	$-258,757,000	$-157,863,000	$-141,429,000	$-112,325,000
Total Operating Income As Reported	$-287,367,000	$-195,078,000	$-154,542,000	$-115,234,000
Net Income Common Stockholders	$-258,757,000	$-157,863,000	$-141,429,000	$-112,325,000
Net Income	$-258,757,000	$-157,863,000	$-141,429,000	$-112,325,000
Net Income Including Noncontrolling Interests	$-258,757,000	$-157,863,000	$-141,429,000	$-112,325,000
Net Income Continuous Operations	$-258,757,000	$-157,863,000	$-141,429,000	$-112,325,000
Pretax Income	$-258,757,000	$-157,863,000	$-141,429,000	$-112,325,000
Special Income Charges	$0	$0	$-12,500,000	$-8,138,000
Operating Income	$-287,367,000	$-195,078,000	$-142,042,000	$-107,096,000
Per Share
Diluted EPS	$-3.90	$-2.45	$-2.92	$-2.40
Basic EPS	$-3.90	$-2.45	$-2.92	$-2.40
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-312,597,000	$-229,116,000	$-139,647,000	$-98,971,000
Total Unusual Items	$28,610,000	$37,215,000	$613,000	$-5,229,000
Total Unusual Items Excluding Goodwill	$28,610,000	$37,215,000	$613,000	$-5,229,000
Reconciled Depreciation	$3,380,000	$3,177,000	$3,008,000	$2,896,000
EBITDA (Bullshit earnings)	$-283,987,000	$-191,901,000	$-139,034,000	$-104,200,000
EBIT	$-287,367,000	$-195,078,000	$-142,042,000	$-107,096,000
Diluted Average Shares	$66,422,000	$64,395,000	$48,449,000	$46,888,000
Basic Average Shares	$66,422,000	$64,395,000	$48,449,000	$46,888,000
Diluted NI Availto Com Stockholders	$-258,757,000	$-157,863,000	$-141,429,000	$-112,325,000
Gain On Sale Of Security	$28,610,000	$37,215,000	$13,113,000	$2,909,000
Research And Development	$245,074,000	$163,550,000	$118,011,000	$82,258,000
Selling General And Administration	$43,838,000	$38,548,000	$30,914,000	$27,195,000
Other Gand A	$43,838,000	$38,548,000	$30,914,000	$27,195,000
Restructuring And Mergern Acquisition	-	$0	$0	$-6,862,000
Tax Provision	-	-	$0	$0
Other Special Charges	-	-	$12,500,000	$15,000,000
Impairment Of Capital Assets	-	-	$0	$0
Write Off	-	-	-	-

Fetched: 2026-06-19

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$499,975,000	$719,815,000	$401,981,000	$299,014,000
Total Assets	$582,983,000	$792,340,000	$465,627,000	$352,735,000
Total Non Current Assets	$48,319,000	$45,181,000	$33,934,000	$35,042,000
Non Current Prepaid Assets	$13,358,000	$9,747,000	$107,000	-
Goodwill And Other Intangible Assets	$27,190,000	$27,190,000	$27,190,000	$27,190,000
Other Intangible Assets	$27,190,000	$27,190,000	$27,190,000	$27,190,000
Current Assets	$534,664,000	$747,159,000	$431,693,000	$317,693,000
Other Current Assets	$14,076,000	$21,178,000	$5,467,000	$12,394,000
Receivables	$2,015,000	$700,000	$2,628,000	$347,000
Accounts Receivable	$2,015,000	$700,000	$2,628,000	$347,000
Cash Cash Equivalents And Short Term Investments	$518,573,000	$725,281,000	$423,598,000	$304,952,000
Cash And Cash Equivalents	$28,871,000	$28,356,000	$34,814,000	$29,429,000
Other Non Current Assets	-	-	$107,000	$104,000
Prepaid Assets	-	-	-	-
Debt
Total Debt	$2,336,000	$3,813,000	$2,542,000	$4,033,000
Long Term Debt And Capital Lease Obligation	$784,000	$2,361,000	$928,000	$2,588,000
Current Debt And Capital Lease Obligation	$1,552,000	$1,452,000	$1,614,000	$1,445,000
Liabilities
Total Liabilities Net Minority Interest	$55,818,000	$45,335,000	$36,456,000	$26,531,000
Total Non Current Liabilities Net Minority Interest	$4,827,000	$5,834,000	$5,331,000	$7,921,000
Other Non Current Liabilities	$4,043,000	$3,473,000	$4,403,000	$5,333,000
Current Liabilities	$50,991,000	$39,501,000	$31,125,000	$18,610,000
Other Current Liabilities	$1,230,000	$942,000	$3,988,000	$990,000
Payables And Accrued Expenses	$48,209,000	$37,107,000	$25,523,000	$16,175,000
Payables	$1,180,000	$3,265,000	$3,494,000	$3,340,000
Accounts Payable	$1,180,000	$3,265,000	$3,494,000	$3,340,000
Equity
Common Stock Equity	$527,165,000	$747,005,000	$429,171,000	$326,204,000
Total Equity Gross Minority Interest	$527,165,000	$747,005,000	$429,171,000	$326,204,000
Stockholders Equity	$527,165,000	$747,005,000	$429,171,000	$326,204,000
Gains Losses Not Affecting Retained Earnings	$3,626,000	$3,314,000	$3,308,000	$1,260,000
Other Equity Adjustments	$3,626,000	$3,314,000	$3,308,000	$1,260,000
Retained Earnings	$-1,813,981,000	$-1,555,224,000	$-1,397,361,000	$-1,255,932,000
Other
Ordinary Shares Number	$66,549,442	$66,374,549	$55,883,377	$47,200,695
Share Issued	$66,549,442	$66,374,549	$55,883,377	$47,200,695
Tangible Book Value	$499,975,000	$719,815,000	$401,981,000	$299,014,000
Invested Capital	$527,165,000	$747,005,000	$429,171,000	$326,204,000
Working Capital	$483,673,000	$707,658,000	$400,568,000	$299,083,000
Capital Lease Obligations	$2,336,000	$3,813,000	$2,542,000	$4,033,000
Total Capitalization	$527,165,000	$747,005,000	$429,171,000	$326,204,000
Additional Paid In Capital	$2,337,453,000	$2,298,849,000	$1,823,168,000	$1,580,829,000
Capital Stock	$67,000	$66,000	$56,000	$47,000
Common Stock	$67,000	$66,000	$56,000	$47,000
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$784,000	$2,361,000	$928,000	$2,588,000
Current Capital Lease Obligation	$1,552,000	$1,452,000	$1,614,000	$1,445,000
Current Accrued Expenses	$47,029,000	$33,842,000	$22,029,000	$12,835,000
Net PPE	$7,771,000	$8,244,000	$6,637,000	$7,748,000
Accumulated Depreciation	$-23,904,000	$-23,464,000	$-22,385,000	$-21,626,000
Gross PPE	$31,675,000	$31,708,000	$29,022,000	$29,374,000
Leases	$10,338,000	$10,285,000	$9,653,000	$9,613,000
Construction In Progress	$1,724,000	$139,000	$787,000	$498,000
Other Properties	$15,681,000	$17,319,000	$14,844,000	$15,809,000
Machinery Furniture Equipment	$3,932,000	$3,965,000	$3,738,000	$3,454,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$489,702,000	$696,925,000	$388,784,000	$275,523,000
Treasury Shares Number	-	-	$0	-

Fetched: 2026-06-19

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-213,659,000	$-159,697,000	$-109,109,000	$-105,560,000
Operating Activities
Operating Cash Flow	$-210,945,000	$-157,778,000	$-107,291,000	$-103,732,000
Cash Flow From Continuing Operating Activities	$-210,945,000	$-157,778,000	$-107,291,000	$-103,732,000
Operating Gains Losses	$12,000	$16,000	-	$2,000
Investing Activities
Capital Expenditure	$-2,714,000	$-1,919,000	$-1,818,000	$-1,828,000
Investing Cash Flow	$209,072,000	$-290,129,000	$-105,782,000	$89,942,000
Cash Flow From Continuing Investing Activities	$209,072,000	$-290,129,000	$-105,782,000	$89,942,000
Net Other Investing Changes	-	-	-	$69,000
Financing Activities
Issuance Of Capital Stock	$0	$432,298,000	$216,222,000	$0
Financing Cash Flow	$2,388,000	$441,449,000	$218,458,000	$4,076,000
Cash Flow From Continuing Financing Activities	$2,388,000	$441,449,000	$218,458,000	$4,076,000
Net Common Stock Issuance	$0	$432,298,000	$216,222,000	$0
Common Stock Issuance	$0	$432,298,000	$216,222,000	$0
Other
End Cash Position	$28,871,000	$28,356,000	$34,814,000	$29,429,000
Beginning Cash Position	$28,356,000	$34,814,000	$29,429,000	$39,143,000
Changes In Cash	$515,000	$-6,458,000	$5,385,000	$-9,714,000
Proceeds From Stock Option Exercised	$2,388,000	$9,151,000	$2,236,000	$4,076,000
Net Investment Purchase And Sale	$211,786,000	$-288,210,000	$-103,964,000	$91,701,000
Sale Of Investment	$596,288,000	$501,714,000	$320,597,000	$280,666,000
Purchase Of Investment	$-384,502,000	$-789,924,000	$-424,561,000	$-188,965,000
Net PPE Purchase And Sale	$-2,714,000	$-1,919,000	$-1,818,000	$-1,828,000
Purchase Of PPE	$-2,714,000	$-1,919,000	$-1,818,000	$-1,828,000
Change In Working Capital	$14,058,000	$-21,601,000	$13,462,000	$-3,898,000
Change In Other Current Liabilities	$-753,000	$-5,636,000	$462,000	$2,726,000
Change In Other Current Assets	$-3,611,000	$-9,640,000	$-3,000	$0
Change In Payables And Accrued Expense	$11,031,000	$11,634,000	$9,384,000	$3,123,000
Change In Prepaid Assets	$8,706,000	$-19,887,000	$5,900,000	$-9,572,000
Change In Receivables	$-1,315,000	$1,928,000	$-2,281,000	$-175,000
Stock Based Compensation	$36,217,000	$34,242,000	$23,890,000	$15,611,000
Amortization Of Securities	$-5,855,000	$-15,749,000	$-6,222,000	$844,000
Depreciation Amortization Depletion	$3,380,000	$3,177,000	$3,008,000	$2,896,000
Depreciation And Amortization	$3,380,000	$3,177,000	$3,008,000	$2,896,000
Net Income From Continuing Operations	$-258,757,000	$-157,863,000	$-141,429,000	$-112,325,000
Asset Impairment Charge	-	-	$0	$0
Deferred Tax	-	-	$0	$0
Deferred Income Tax	-	-	$0	$0
Repayment Of Debt	-	-	-	$0
Issuance Of Debt	-	-	-	$0
Net Issuance Payments Of Debt	-	-	-	$0
Net Long Term Debt Issuance	-	-	-	$0
Long Term Debt Payments	-	-	-	$0
Long Term Debt Issuance	-	-	-	$0
Other Non Cash Items	-	-	-	$-6,862,000
Depreciation	-	-	-	$2,896,000

Fetched: 2026-06-19